RemeGen Co., Ltd. Fundamental Analysis
RemeGen Co., Ltd. (9995.HK) shows moderate financial fundamentals with a PE ratio of 26.35, profit margin of 37.91%, and ROE of 41.60%. The company generates $3.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 9995.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent9995.HK demonstrates superior asset utilization.
Valuation Score
Moderate9995.HK shows balanced valuation metrics.
Growth Score
Moderate9995.HK shows steady but slowing expansion.
Financial Health Score
Excellent9995.HK maintains a strong and stable balance sheet.
Profitability Score
Excellent9995.HK achieves industry-leading margins.
Key Financial Metrics
Is 9995.HK Expensive or Cheap?
P/E Ratio
9995.HK trades at 26.35 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 9995.HK's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values RemeGen Co., Ltd. at 8.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 60.16 times EBITDA. This signals the market has high growth expectations.
How Well Does 9995.HK Make Money?
Net Profit Margin
For every $100 in sales, RemeGen Co., Ltd. keeps $37.91 as profit after all expenses.
Operating Margin
Core operations generate 8.98 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $41.60 in profit for every $100 of shareholder equity.
ROA
RemeGen Co., Ltd. generates $17.29 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
RemeGen Co., Ltd. generates limited operating cash flow of $254.98M, signaling weaker underlying cash strength.
Free Cash Flow
RemeGen Co., Ltd. generates weak or negative free cash flow of $46.44M, restricting financial flexibility.
FCF Per Share
Each share generates $0.08 in free cash annually.
FCF Yield
9995.HK converts 0.14% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
26.35
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.97
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.53
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.58
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.42
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How 9995.HK Stacks Against Its Sector Peers
| Metric | 9995.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 26.35 | 29.63 | Better (Cheaper) |
| ROE | 41.60% | 223.00% | Weak |
| Net Margin | 37.91% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.53 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 1.58 | 4.30 | Neutral |
| ROA | 17.29% | -379.00% (disorted) | Strong |
9995.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews RemeGen Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation